RT Journal Article
SR Electronic
T1 WASH interventions and child diarrhea at the interface of climate and socioeconomic position in Bangladesh
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.09.23293893
DO 10.1101/2023.08.09.23293893
A1 Ante-Testard, Pearl Anne
A1 Rerolle, Francois
A1 Nguyen, Anna T.
A1 Ashraf, Sania
A1 Parvez, Sarker Masud
A1 Naser, Abu Mohammed
A1 Benmarhnia, Tarik
A1 Rahman, Mahbubur
A1 Luby, Stephen P.
A1 Benjamin-Chung, Jade
A1 Arnold, Benjamin F.
YR 2023
UL http://medrxiv.org/content/early/2023/08/13/2023.08.09.23293893.abstract
AB Many diarrhea-causing pathogens are climate-sensitive, and the poorest populations are often most vulnerable to climate-related transmission. Household Water, Sanitation, and Handwashing (WASH) interventions constitute one potential effective strategy to reduce diarrhea among children, especially among low-income households. Here, capitalizing on a cluster randomized trial population (360 clusters, 8,440 measurements among children < 3 years) in rural Bangladesh, one of the world’s most climate-sensitive regions regarding precipitation regimes, we show that improved WASH substantially reduces diarrhea risk with largest benefits among poorest children and during the monsoon season. We extrapolated trial results to rural Bangladesh regions using high-resolution geospatial layers to identify areas most likely to benefit. We estimated that a similar intervention at scale could prevent 734 cases per 1,000 children per month during the seasonal monsoon, with marked heterogeneity by region. The analysis demonstrates how to extend large-scale trials to inform WASH strategies among climate-sensitive and low-income populations.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01590095Funding StatementThis study was funded by the Bill and Melinda Gates Foundation to the University of California, Berkeley (OPPGD759, Principal Investigator: John M. Colford Jr., MD, PhD) and the National Institute of Allergy and Infectious Diseases (R01-AI166671, Principal Investigator: Benjamin F. Arnold, PhD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol of the original study was approved by the Ethical Review Committee at the International Centre for Diarrhoeal Disease Research, Bangladesh (PR-11063), the Committee for the Protection of Human Subjects at the University of California, Berkeley (2011-09-3652), the Institutional Review Board at Stanford University (25863) and at the University of California, San Francisco (22-36722).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe pre-analysis plan, de-identified data and analysis scripts are available through the Open Science Framework (https://osf.io/xwndg/). https://osf.io/xwndg/